Literature DB >> 21242967

The constitutive activity of the ALK mutated at positions F1174 or R1275 impairs receptor trafficking.

P Mazot1, A Cazes, M C Boutterin, A Figueiredo, V Raynal, V Combaret, B Hallberg, R H Palmer, O Delattre, I Janoueix-Lerosey, M Vigny.   

Abstract

Anaplastic lymphoma kinase (ALK) is a receptor tyrosine kinase (RTK), which is transiently expressed during development of the central and peripheral nervous system. ALK has been recently identified as a major neuroblastoma predisposition gene and activating mutations have also been identified in a subset of sporadic neuroblastoma tumors. Two hot spots of ALK mutations have been observed at positions F1174 and R1275. Here, we studied stably transfected cell lines expressing wild-type or F1174L- or R1275Q-mutated ALK in parallel with a neuroblastoma cell line (CLB-GE) in which the allele mutated at position F1174 is amplified. We observed that the mutated ALK variants were essentially intracellular and were largely retained in the reticulum/Golgi compartments. This localization was corroborated by a defect of N-linked glycosylation. Although the mutated receptors exhibited a constitutive activation, the minor pool of receptor addressed to the plasma membrane was much more tyrosine phosphorylated than the intracellular pool. The use of antagonist monoclonal antibodies suggested that the constitutive activity of the mutated receptors did not require the dimerization of the receptor, whereas adequate dimerization triggered by agonist monoclonal antibodies increased this activity. Finally, kinase inactivation of the mutated receptors restored maturation and cell-surface localization. Our results show that constitutive activation of ALK results in its impaired maturation and intracellular retention. Furthermore, they provide a rationale for the potential use of kinase inhibitors and antibodies in ALK-dependent tumors.

Entities:  

Mesh:

Substances:

Year:  2011        PMID: 21242967     DOI: 10.1038/onc.2010.595

Source DB:  PubMed          Journal:  Oncogene        ISSN: 0950-9232            Impact factor:   9.867


  25 in total

1.  Differential inhibitor sensitivity of anaplastic lymphoma kinase variants found in neuroblastoma.

Authors:  Scott C Bresler; Andrew C Wood; Elizabeth A Haglund; Joshua Courtright; Lili T Belcastro; Jefferson S Plegaria; Kristina Cole; Yana Toporovskaya; Huaqing Zhao; Erica L Carpenter; James G Christensen; John M Maris; Mark A Lemmon; Yaël P Mossé
Journal:  Sci Transl Med       Date:  2011-11-09       Impact factor: 17.956

2.  Antibody targeting of anaplastic lymphoma kinase induces cytotoxicity of human neuroblastoma.

Authors:  E L Carpenter; E A Haglund; E M Mace; D Deng; D Martinez; A C Wood; A K Chow; D A Weiser; L T Belcastro; C Winter; S C Bresler; M Vigny; P Mazot; S Asgharzadeh; R C Seeger; H Zhao; R Guo; J G Christensen; J S Orange; B R Pawel; M A Lemmon; Y P Mossé
Journal:  Oncogene       Date:  2012-01-23       Impact factor: 9.867

Review 3.  Emerging importance of ALK in neuroblastoma.

Authors:  Anna M Azarova; Gargi Gautam; Rani E George
Journal:  Semin Cancer Biol       Date:  2011-09-16       Impact factor: 15.707

4.  Proliferation and Survival of Embryonic Sympathetic Neuroblasts by MYCN and Activated ALK Signaling.

Authors:  Marco Kramer; Diogo Ribeiro; Marie Arsenian-Henriksson; Thomas Deller; Hermann Rohrer
Journal:  J Neurosci       Date:  2016-10-05       Impact factor: 6.167

5.  The R1275Q neuroblastoma mutant and certain ATP-competitive inhibitors stabilize alternative activation loop conformations of anaplastic lymphoma kinase.

Authors:  Linda F Epstein; Hao Chen; Renee Emkey; Douglas A Whittington
Journal:  J Biol Chem       Date:  2012-08-29       Impact factor: 5.157

6.  Cooperative Cross-Talk between Neuroblastoma Subtypes Confers Resistance to Anaplastic Lymphoma Kinase Inhibition.

Authors:  Xiaocai Yan; Colin R Kennedy; Sarah B Tilkens; Olena Wiedemeier; Hong Guan; Jong-In Park; Andrew M Chan
Journal:  Genes Cancer       Date:  2011-05

7.  Ethanol activates midkine and anaplastic lymphoma kinase signaling in neuroblastoma cells and in the brain.

Authors:  Donghong He; Hu Chen; Hisako Muramatsu; Amy W Lasek
Journal:  J Neurochem       Date:  2015-08-11       Impact factor: 5.372

Review 8.  New insights into the genetics of neuroblastoma.

Authors:  Srishma Sridhar; Batool Al-Moallem; Hawra Kamal; Marta Terrile; Raymond L Stallings
Journal:  Mol Diagn Ther       Date:  2013-04       Impact factor: 4.074

9.  The ALK/ROS1 Inhibitor PF-06463922 Overcomes Primary Resistance to Crizotinib in ALK-Driven Neuroblastoma.

Authors:  Nicole R Infarinato; Jin H Park; Kateryna Krytska; Hannah T Ryles; Renata Sano; Katherine M Szigety; Yimei Li; Helen Y Zou; Nathan V Lee; Tod Smeal; Mark A Lemmon; Yael P Mossé
Journal:  Cancer Discov       Date:  2015-11-10       Impact factor: 39.397

10.  Selective therapeutic targeting of the anaplastic lymphoma kinase with liposomal siRNA induces apoptosis and inhibits angiogenesis in neuroblastoma.

Authors:  Daniela Di Paolo; Chiara Ambrogio; Fabio Pastorino; Chiara Brignole; Cinzia Martinengo; Roberta Carosio; Monica Loi; Gabriella Pagnan; Laura Emionite; Michele Cilli; Domenico Ribatti; Theresa M Allen; Roberto Chiarle; Mirco Ponzoni; Patrizia Perri
Journal:  Mol Ther       Date:  2011-08-09       Impact factor: 11.454

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.